Drug Approval | June 07, 2022
Zydus Lifesciences receives USFDA approval for Adapalene and Benzoyl Peroxide Topical Gel
The drug will be manufactured at the group’s topical facility at Ahmedabad
The drug will be manufactured at the group’s topical facility at Ahmedabad
Successfully removed peanut from the child’s left lung through bronchoscopy
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
With the commercialization of Qvella technology for Positive Blood Culture (PBC) processing, healthcare facilities can now get results up to 24 hours faster than current methods
The symposium was organized by the Gut Microbiota and Probiotic Science Foundation (India) and Medanta Institute of Education and Research, Gurugram, and Amity University, Gurugram
A major unresolved question in the field, however, is how do this machinery rapidly searches for and finds rare stretches of damage amid the "vast fields" of undamaged DNA
Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre In conversation with Thomas C Thottathil, Editor, www.indianpharmapost.com identified key areas that the company is focusing on in its Mission 2025
The meeting was co-organized by World Health Organization’s Country Office for India, World Animal Protection India and ReAct Asia Pacific
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
Subscribe To Our Newsletter & Stay Updated
